New treatment makes migranines vanish

“It’s a very severe pain, often times throbbing occurring on one side of the head, often times behind the eye,” Dr. Sugimoto said. “You’ll do anything to get rid of that pain.”
At the Cedar-Crosse Research Center in Chicago’s South Loop, a study called ‘Promise One’ is hoping to give migraine sufferers the relief they’ve been looking for.
The drug is called ‘ALD403.’ It’s given to a patient through an I-V once for an hour, every three months.
It is now in phase three of the trial before it goes to the Food and Drug Administration for approval. That approval could come in the next two to three years.
But for potential trial patients like Spiller, the drug could be a life line.
“It for me would mean to get my life back. That’s what it means to me. For me to live and not just exist which is what I’ve basically been doing,” Spiller said.

Drug to prevent migraines being researched by chicago doctor

CHICAGO (CBS) — It can strike quick and leave you unable to do anything, sometimes for days. Migraines debilitate more than 33 million people nationwide. Now a new clinical study is showing positive results in preventing them.
“Migraines is an invisible sickness. People don’t know that you’re suffering,” said police officer Tina Olsen.
She suffers from chronic headaches 25 days out of a month. Often they turn into a migraine.
“I’ve missed days of work because of it. I’ve had to delay plans,” she said.
Olsen’s doctor, Danny Sugimoto, of Chicago’s Cedar-Crosse Research Center, is involved in a national test study of a protein injection called ALD403. The intravenous treatment has been shown to reduce and even prevent migraines.
“For migraine prevention, there’s nothing like it,” Sugimoto said. “I’m a migraine sufferer, and I’ve been doing drug research for over 27 years, and for me it’s very exciting. I agree, it is a breakthrough”
The research is still ongoing, and not yet published, but Olsen is encouraged.
“I’m excited to have a medication that will take care of three months at a time,” she said.
Sugimoto said, so far, no one has complained of any side effects from ALD403.
“Everyone has been loving the drug. Again, we are blinded, and a lot of people have said that it’s the first time they’ve been headache-free in years,” Sugimoto said he hopes the drug passes regulatory guidelines to become
widely available in the next two years.
“Please hurry. We, us migraine sufferers, we’re waiting for this,” Olsen said. ALD403 is being tested by the pharmaceutical company Alder. It would be the first drug designed specifically to prevent migraines.